vial of the long-acting injectable PrEP medication Apretude


cabotegravir extended-release injectable suspension CAB-LA

FDA approved only for the prevention of HIV
PrEP Drug Class Icon
Pre-Exposure Prophylaxis

Standard Dose

For HIV-negative adults and adolescents (male, female, and transgender) weighing at least 77 pounds (35 kg) for the prevention of HIV. One long-acting intramuscular gluteal (butt muscle) 600 mg injection (3 mL) monthly for the first two months and then one injection every 2 months thereafter. No food restrictions.

Daily oral lead-in therapy for about a month to determine tolerability is optional before injections begin, consisting of a 30 mg tablet of Vocabria. Initiate injections on the last day of oral lead-in. Individuals who were on daily oral PrEP with Descovy or Truvada can transition directly to Apretude injections once their HIV-negative status is confirmed. If up to 8 weeks of treatment is missed (less than or equal to 2 months), restart injections with the 600 mg dose of CAB-LA as soon as possible, and then dose every 2 months thereafter. If more than 8 weeks of therapy have been missed, restart treatment with a 600 mg dose as soon as possible, followed a month later with another 600 mg dose, and then dose every two months thereafter. The oral medication can also be used as “bridging” if shots cannot be obtained on time—see package insert for instructions on planned and unplanned missed injections. The effect of severe liver impairment on cabotegravir is unknown. Longer needles, two inches (not included in the dosing kit), may be required for people with a higher BMI (body mass index) of 30 or more.

  • Oral cabotegravir is not available unless being prescribed cabotegravir LA.
  • See package insert for more complete information on potential side effects and interactions.


ViiV Healthcare
(877) 844-8872


$4,440 per vial, based on WAC

Potential Side Effects and Toxicity

Potential Drug Interactions

More Information

Doctor Comments

Activist Comments